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Abstract
Introduction: Metabolic bone disease is one of the major 
complications of end stage renal disease (ESRD). We aimed 
in this investigation to explore the role of Technetium-
99m sestamibi (99mTc MIBI) scintigraphy in the pre-
operative assessment of refractory hyperparathyroidism in 
hemodialysis (HD) patients. 
Methods: Dual-phase 99mTc MIBI parathyroid scintigraphy 
was performed for 23 patients with ESRD who have 
persistent intact parathyroid hormone (iPTH) levels 
exceeding 300 pg/ml. Based on scintigraphy results, 13 
patients underwent neck exploration during which only 
glands with positive scintigraphy findings were removed. 
Results: Among the six patients who had iPTH levels 
< 800 pg/ml, only one patient had positive scintigraphy 
findings (16.7%). Among the 17 patients who had iPTH 
levels ≥ 800 pg/ml, 16 patients had positive scintigraphy 
findings (94.1%). 99mTc MIBI scan detected 23 positive 
sites of focal trace uptake in those 17 patients. Partial 
parathyroidectomy was performed for 13 patients, removing 
in total 19 glands, while four patients declined surgery. 
On histological examination, 12 glands showed diffuse 
hyperplasia, four glands showed nodular hyperplasia and 
three glands revealed parathyroid adenoma. The three 
glands with parathyroid adenoma were correctly identified 
prior to surgery by 99mTc MIBI scintigraphy.  The long-term 
outcomes of these patients are now being monitored. 
Conclusion: ESRD patients with iPTH level ≥ 800 pg/
ml are more likely to have positive sites of focal tracer 
uptake on MIBI scan than patients with lower iPTH levels. 
Dual-phase 99mTc MIBI scintigraphy has the ability to 
correctly identify parathyroid adenoma prior to surgical 
exploration in these patients.
Keywords: Hyperparathyroidism, parathyroid adenoma, 
parathyroid hyperplasia, scintigraphy, 99mTc sestamibi
Introduction
Secondary hyperparathyroidism (SHP) is one of the 
serious complications of end stage renal disease (ESRD) 
[1]. A number of factors may contribute to SHP, such as 
hypocalcemia, hyperphosphatemia, vitamin D deficiency 
and the reduction of vitamin D and calcium sensing 
receptors in the parathyroid gland [2]. Through poorly 
understood mechanisms, these factors lead initially to 
diffuse and polyclonal cell proliferation. Subsequently, 
in some glands, nodular growth occurs within diffuse 
hyperplastic tissue. These nodules represent autonomous 
and monoclonal growth, likely corresponding to the 
so-called ‘tertiary hyperparathyroidism’ [3].
Technetium-99m sestamibi (99mTc MIBI) scintigraphy 
is now widely used as an alternative method to thallium 
chloride-201 (201TI) / 99mTc subtraction scintigraphy 
which is no longer used in clinical practice for imaging 
of parathyroid glands [4, 5]. Dual-phase 99mTc MIBI scan 
has demonstrated high specifity, despite low sensitivity, 
in locating parathyroid glands in patients with secondary 
hyperparathyroidism [6].
99mTc MIBI is concentrated within the cells through active 
transport and passive diffusion, a process facilitated by 
negative trans-membrane potential found in metabolically 
hyperactive cells and by the lipophilic nature of 99mTc 
MIBI [7]. As increased numbers of mitochondria have 
been found in hyperactive parathyroid cells, intra-
mitochondrial sequestration may be an additional 
mechanism of 99mTc MIBI tissue binding [7]. This may 
account for slower 99mTc MIBI washout from hyperactive 
parathyroid compared to normal thyroid and parathyroid 
tissues [8]. 
The aim of the present study was to evaluate the role of 
dual-phase 99mTc MIBI scintigraphy in the pre-operative 
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assessment of parathyroid glands of uremic patients with 
refractory hyperparathyroidism. 
Methods
The study included ESRD patients maintained on regular 
hemodialysis (HD) who had persistent intact parathyroid 
hormone (iPTH) levels more than 300 pg/ml using specific 
radioimmunoassay. Informed consent was obtained from 
all patients for a dual-phase 99mTc MIBI scan. Fifteen mCi 
(550 MBq) of 99mTc MIBI was intravenously injected 
in all patients. Twenty minutes post-injection, planar 
anterior imaging of the neck and the upper thorax of 
supine patients was performed (early phase) using a large 
field gamma camera with low-energy, high resolution, 
parallel-hole collimator, 20% energy window centered 
at 140 Kev, 128x128 matrix for static images and zoom 
2.65. The second phase (delayed phase) was performed 
two hours after the injection of 99mTc MIBI. Scans were 
performed on the following day of a dialysis session. 
All patients had preliminary 99mTc pertechnetate thyroid 
scintigraphy performed one week earlier to exclude the 
presence of thyroid hot nodules or other focal lesions in 
the thyroid gland. Images were separately scrutinized 
by two nuclear medicine physicians for foci of 
abnormally active trace uptake in the expected location 
of parathyroid glands or other ectopic sites. Patients with 
positive scintigraphy findings were referred for partial 
parathyroidectomy, removing only glands identified to 
have active foci of trace uptake. Unpaired Student's t test 
was used to compare means and Chi square test was used 
to compare proportions. P value < 0.05 was considered 
statistically significant. 
Results
The study group included 23 patients with ESRD and 
refractory hyperparathyroidism. Their mean age was 
Table 1:  Clinical and biochemical data, scintigraphy findings and histological diagnosis of studied patients 












Site and number  
of positive glands 
Histological 
pattern
1 52 20 4.7 7.2 330 Negative - -
2 48 45 4.4 8.5 340 Negative
3 56 50 4.3 7.8 341 Negative - -
4 45 40 4.8 8.3 535 Negative - -
5 30 36 4.5 9.0 560 Negative - -
6 27 108 8.2 9.5 780 Positive RL (1) DHP
7 63 90 4.5 7.7 890 Positive LL (1) DHP
8 65 120 5.0 8.3 933 Negative - -
9 63 108 8.2 9.5 966 Positive LL (1) DHP
10 63 118 8.2 9.5 1000 Positive LL (1) DHP
11 50 125 4.6 7.3 1055 Positive RL+LL (2) NHP
12 40 132 4.8 7.7 1078 Positive RL (1) -
13 60 90 7.4 9.1 1120 Positive RL+LL (2) NHP
14 70 120 4.8 10 1200 Positive LU (1) AD
15 63 108 2.5 9.5 1200 Positive LL (1) -
16 63 120 4.5 9.2 1200 Positive RL+LL (2) NHP
17 50 85 4.0 9.5 1215 Positive RL+LL (2) NHP
18 63 80 3.9 10.2 1500 Positive LL (1) -
19 60 100 2.2 10.2 1550 Positive RL (1) AD
20 40 132 3.8 9.4 1712 Positive RL+LL (2) NHP
21 58 90 4.9 9.8 1800 Positive RL (1) -
22 40 180 4.8 10.3 2000 Positive RL (1) AD
23 60 96 5.5 8 2161 Positive RL+LL (2) NHP 
DHP = Diffuse Hyperplasia, NHP = Nodular Hyperplasia, AD = Adenoma, LL = Left Lower, RL = Right Lower, LU = Left Upper
Arab Journal of Nephrology and Transplantation
18
Kandeel et al
53.4 years (SD 11.7; range 27-70 years). Patients have 
been on regular HD for a mean duration of 95.3 months 
(SD 37.4; range 20-180 months). The majority of patients 
presented with variable symptoms and signs related to 
metabolic bone disease despite regular treatment with 
calcium carbonate and calcitriol. This treatment was not 
interrupted during the course of the present study. The 
mean pre-dialysis concentration of serum calcium was 
8.9 mg/dl (SD 1; range 7.2-10.3 mg/dl) and the mean 
pre-dialysis concentration of serum phosphorus was 4.9 
mg/dl (SD 1.6; range 2.2-8.2 mg/dl). The mean level 
of circulating iPTH was 1107 pg/ml (SD 512; range 
330-1161 pg/ml), assayed by specific radioimmunoassay. 
Clinical and biochemical data of individual patients are 
summarized in Table 1.
Thyroid scintigraphy was normal in all patients. Early 
phase 99mTc MIBI scintigraphy showed normal thyroid 
uptake in all cases associated with focal extra-thyroid hot 
spots in the anatomical sites of parathyroid glands region 
in scintigraphy positive cases. In the delayed phase, 99mTc 
MIBI uptake in the thyroid decreased while its relative 
focal concentration increased in the parathyroid tissue. 
Two examples of 99mTc MIBI positive parathyroid scans 
are shown in Figure 1. 
Overall, 99mTc MIBI scan detected 23 positive sites 
of focal trace uptake in the 17 patients with positive 
findings. Among the six patients who had iPTH level 
< 800 pg/ml, only one patient had positive scintigraphy 
findings (16.7%). Among the 17 patients who had iPTH 
level ≥ 800 pg/ml, 16 patients had positive scintigraphy 
findings (94.1%). 
Patients with positive 99mTc MIBI scintigraphy scans 
had higher mean iPTH concentrations (1319±400 versus 
507±233 pg/ml, P < 0.0001), higher mean serum calcium 
concentration (9.2±0.9 versus 8.2±0.6 mg/dl; P = 0.01), 
and longer mean dialysis duration (111±24 versus 52±35 
months; P < 0.0001) compared to those with negative 
scans. Age and serum phosphorus level were not 
significantly different between the two groups. 
Thirteen patients with positive 99mTc MIBI scintigraphy 
findings had partial parathyroidectomy, removing in total 
19 glands with focal trace intake, while four patients 
declined surgery. On histological examination of these 
glands, 12 glands showed diffuse hyperplasia (increased 
number of parenchymal cells with normal lobular 
structures), four glands showed nodular hyperplasia (at 
least one well circumscribed, encapsulated and virtually 
fat cell-free accumulation of parenchymal cells) and 
three glands revealed parathyroid adenoma. 99mTc 
Figure 1: Dual phase 99mTc MIBI scan at 20 min (early phase) on the left and at 2 hours (delayed phase) on the right in two 
patients with uremic hyperparathyroidism: (A) shows right lower parathyroid gland adenoma and (B) shows bilateral lower 
parathyroid glands hyperplasia  
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MIBI scintigraphy correctly identified the three glands 
with parathyroid adenoma prior to surgery. In addition, 
glands found to have nodular hyperplasia had higher 
trace uptake during scintigraphy and were associated 
with higher iPTH levels (> 1000 pg/ml) than glands with 
diffuse hyperplasia. The long-term outcomes of patient 
who underwent partial parathyroidectomy and those who 
declined surgery are now being monitored. 
Discussion
Significant morbidity and mortality can result from 
SHP in patients with ESRD [9]. The Kidney Disease 
Outcomes Quality Initiative (K/DOQI) Guidelines define 
parathyroid over-activity in ESRD patients by an iPTH 
level > 300 pg/ml. The same guidelines recommend 
parathyroidectomy for patients with persistent levels of 
iPTH > 800 pg/ml, associated with hypercalcemia and/or 
hyperphosphatemia that are refractory to medical therapy 
[10]. 
Abnormal parathyroid glands can be located using various 
techniques in patients with SHP. 99mTc MIBI scintigraphy 
has higher sensitivity and specifity than ultrasound in 
case of SHP [6]. Slower MIBI washout has been observed 
in hyperactive parathyroid glands compared with normal 
thyroids and parathyroids [11]. Piga et al stated that 99mTc 
MIBI scans do not simply reveal parathyroid enlargement 
but rather identify hyperfunctioning parathyroid glands 
in uremic patients with SHP [12]. In the present study, 
99mTc MIBI detected hyper-functioning glands in 17 out 
of 23 HD patients with SHP (73.9 %). Custodio et al 
demonstrated that 88.8% of their 18 patients with SHP had 
hyperactive glands on 99mTc MIBI scan [13]. An important 
factor that may influence the rate of positive scintigraphy 
findings in patients with SHP and parathyroid adenoma 
is the variable expression of metabolism transporters, 
such as p-glycoprotein (P-GP) or multidrug resistance-
associated protein (MRP) in the parathyroid glands, 
which may function as a drug transporter for 99mTc 
MIBI [14, 15]. In our opinion, SPECT technique may 
increase the sensitivity of 99mTc MIBI scan in detecting 
hyper-functioning parathyroid glands compared to planar 
images.
In the current study, we observed that patients with 
positive 99mTc MIBI scans had higher iPTH concentrations 
and longer duration on dialysis compared to patients 
with negative scans. This concurs with the findings of 
previous reports [12, 13, 16]. The association between 
high trace uptake and nodular hyperplasia on histological 
examination in this study was expected. It is well known 
that glands with nodular growth patterns are heavier and 
show higher proliferative activity than diffusely hyper-
plastic glands [17, 18]. Torregrosa et al demonstrated that 
99mTc MIBI scintigraphy accurately reflects the functional 
status of the hyper-plastic parathyroid glands, with higher 
uptake grades correlating with the active growth phase 
[19]. 
According to the K/DOQI guidelines, effective 
surgical therapy of severe hyperparathyroidism can 
be accomplished by subtotal parathyroidectomy 
or total parathyroidectomy with parathyroid tissue 
autotransplantation [10]. We referred patients with positive 
scintigraphy findings for partial parathyroidectomy, 
removing only glands identified to have active foci of 
trace uptake. The long-term outcomes of these patients 
are now being monitored.
Conclusion 
In addition to biochemical data, 99mTc MIBI parathyroid 
scan can be a useful screening method to assess the 
functional status of parathyroid glands in uremic patients 
with secondary hyperparathyroidism as well as to detect 
functional autonomy (tertiary hyperparathyroidism).
References
1. Goodman WG. Recent developments in the 
management of secondary hyperparathyroidism. Kidney 
Int. 2001 Mar;59(3):1187–201.
2. Hory B, Drueke TB. The parathyroid–bone axis in 
uremia: new insights into old questions. Curr Opin 
Nephrol Hypertens. 1997 Jan;6(1):40–8.
3. Drueke TB. The pathogenesis of parathyroid gland 
hyperplasia in chronic renal failure. Kidney Int. 1995 
Jul;48(1):259–72.
4. O'Doherty MJ, Kettle AG, Wells P. Collins RE, 
Coakley AJ. Parathyroid imaging with technetium-99m-
sestamibi: preoperative localization and tissue uptake 
studies. J Nucl Med. 1992 Mar;33(3):313-8.
5. Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K. 
Imaging of the parathyroid in chronic renal failure: 
diagnostic and therapeutic aspects. Curr Opin Nephrol 
Hypertens. 1997 Jul;6(4):349-55.
6. Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Léger 
A, Lopez J, Acuña G, Petraglia A, Alvarez A, Caorsi H, 
Drüeke T, Ambrosoni P. [(99m) Tc]-sestamibi parathyroid 
scintigraphy in chronic haemodialysis patients: static and 
dynamic explorations. Nephrol Dial Transplant. 2000 
Aug;15(8):1201–6.
7. Piwnica-Worms D, Holman BL. Noncardiac 
applications of hexakis (alkylisonitrile) technetium-99m 
complexes. J Nucl Med. l990 Jul;3l(7):1166-7.
Arab Journal of Nephrology and Transplantation
20
Kandeel et al
8. Taillefer R, Boucher Y. Potvin C, Lambert R. Detection 
and localization of parathyroid adenomas in patients with 
hyperparathyroidism using a single radionuclide imaging 
procedure with technetium-99m-sestamibi (double-phase 
study). J Nucl Med. 1992 Oct;33(10):1801-7.
9. Slatopolsky E. The role of calcium, phosphorus and 
vitamin D metabolism in the development of secondary 
hyperparathyroidism. Nephrol Dial Transplant. 1998;13 
Suppl 3:3–8.
10. National Kidney Foundation. K/DOQI clinical 
practice guidelines for bone metabolism and disease in 
chronic kidney disease. Am J Kidney Dis. 2003 Oct;42(4 
Suppl 3):S1-201.
11. Torregrosa JV, Palomar MR, Pons F, Sabater L, 
Gilabert R, Llovera J, Fernandez-Cruz L. Has double-
phase MIBI scintigraphy usefulness in the diagnosis of 
hyperparathyroidism? Nephrol Dial Transplant. 1998;13 
Suppl 3:37–40.
12. Piga M, Bolasco P, Satta L, Altieri P, Loi G, Nicolosi 
A, Tarquini A, Mariotti S. Double phase parathyroid 
technetium-99m MIBI scintigraphy to identify functional 
autonomy in secondary hyperparathyroidism. J Nucl 
Med. 1996 Apr;37(4):565–9.
13. Custodio MR, Montenegro F, Costa AF, dos Reis 
LM, Buchpiguel CA, Oliveira SG, Noronha IL, Moyses 
RM, Jorgetti V. MIBI scintigraphy, indicators of cell 
proliferation and histology of parathyroid glands 
in uraemic patients. Nephrol Dial Transplant. 2005 
Sep;20(9):1898–903.
14. Sun SS, Shiau YC, Lin CC, Kao A, Lee CC. Correlation 
between P-glycoprotein (P-gp) expression in parathyroid 
and Tc-99m MIBI parathyroid image findings. Nucl Med 
Biol. 2001 Nov;28(8):929–33.
15. Yamaguchi S, Yachiku S, Hashimoto H, Kaneko S, 
Nishihara M, Niibori D, Shuke N, Aburano T. Relation 
between technetium 99m-methoxyisobutylisonitrile 
accumulation and multidrug resistance protein in the 
parathyroid glands. World J Surg. 2002 Jan;26(1):29–34.
16. Hung GU, Wang SJ, Lin WY. Tc-99m MIBI 
parathyroid scintigraphy and intact parathyroid hormone 
levels in hyperparathyroidism. Clin Nucl Med. 2003 
Mar;28(3):180–5.
17. Drueke TB. The pathogenesis of parathyroid gland 
hyperplasia in chronic renal failure. Kidney Int. 1995 
Jul;48(1):259–72.
18. Parfitt AM. The hyperparathyroidism of chronic 
renal failure: A disorder of growth. Kidney Int. 1997 
Jul;52(1):3–9.
19. Torregrosa JV,  Fernández-Cruz L, Canalejo A, Vidal S, 
Astudillo E, Almaden Y, Torregrosa JV, Pons F, Rodriguez 
M. (99m)Tc-sestamibi scintigraphy and cell cycle in 
parathyroid glands of secondary hyperparathyroidism. 
World J Surg. 2000 Nov;24(11):1386–90.
